Evidence map›Paper›PMID 35777868›Full record

ArticleBMJ open2022

Integrating hepatitis B care and treatment with existing HIV services is possible: cost of integrated HIV and hepatitis B treatment in a low-resource setting: a cross-sectional hospital-based cost-minimisation assessment.

David Livingstone Ejalu, Joan N Mutyoba, Claude Wandera, Emmanuel Seremba, Andrew Kambugu, Alex Muganzi, Racheal Beyagira, Jacinto Amandua, Kaggwa Mugagga, Philippa Easterbrook and 1 more

Abstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David Livingstone EjaluSchool of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.ORCID 0000-0003-1828-6046
Joan N MutyobaDepartment of Biostatistics and Epidemiology, Makerere University College of Health Sciences, School of Public health, Kampala, Uganda.
Claude WanderaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Emmanuel SerembaKiruddu National Referral Hospital, Kampala, Uganda.
Andrew KambuguInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Alex MuganziInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Racheal BeyagiraMinistry of Health, Kampala, Uganda.
Jacinto AmanduaMinistry of Health, Kampala, Uganda.
Kaggwa MugaggaWorld Health Organization, Country Office, Kampala, Uganda.
Philippa EasterbrookWorld Health Organization, Geneva, Switzerland.
Ponsiano OcamaMakerere University College of Health Sciences, School of Medicine, Kampala, Uganda ponsiano.ocama@gmail.com.ORCID 0000-0002-6120-1055

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundHepatitis B and HIV care share health system challenges in the implementation of primary prevention, screening, early linkage to care, monitoring of therapeutic success and long-term medication adherence.

settingArua regional referral hospital (RRH) and Koboko district hospital (DH), the West Nile region of Uganda.

designA cross-sectional hospital-based cost minimisation study from the providers' perspective considers financial costs to measure the amount of money spent on resources used in the stand-alone and integrated pathways. DATA SOURCES: Clinic inputs and procurement invoices, budgetary documents, open market information and expert opinion. Data were extracted from 3121 files of HIV and hepatitis B virus (HBV) monoinfected patients from the two study sites.

objectiveTo estimate provider costs associated with running an integrated HBV and HIV clinical pathway for patients on lifelong treatment in low-resource setting in Uganda. OUTCOME MEASURES: The annual cost per patient was simulated based on the total amount of resources spent for all the expected number of patient visits to the facility for HBV or HIV care per year.

resultsFindings showed that Arua hospital had a higher cost per patient in both clinics than did Koboko Hospital. The cost per HBV patient was US$163.59 in Arua and US$145.76 in Koboko while the cost per HIV patient was US$176.52 in Arua and US$173.23 in Koboko. The integration resulted in a total saving of US$36.73 per patient per year in Arua RRH and US$17.5 in Koboko DH.

conclusionThe application of the integrated Pathway in HIV and HBV patient management could improve hospital cost efficiency compared with operating stand-alone clinics.

Indexed as

Hepatitis BHIV InfectionsCross-Sectional StudiesHepatitis B virusHospital CostsHospitalsHumanshealth economicshealth policyorganisation of health servicesquality in health care

Identifiers

PMID35777868
PMCPMC9252200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.